Ethanol and liver: Recent insights into the mechanisms of ethanol-induced fatty liver

World Journal of Gastroenterology

Volumn 20, Issue 40, 2014, Pages 14672-14685

  Liu, Jinyao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alcohol; Alcoholic liver disease; Bone marrow derived cell; Fatty liver; Hepatic stellate cell; Tumor necrosis factor

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STEROL REGULATORY ELEMENT BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ALCOHOL; ANTIINFLAMMATORY AGENT; AUTACOID; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ALCOHOLIC FATTY LIVER; BONE MARROW CELL; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEEDBACK SYSTEM; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; STELLATE CELL; ADVERSE EFFECTS; ANIMAL; DRINKING BEHAVIOR; DRUG EFFECTS; FATTY LIVER, ALCOHOLIC; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

ALCOHOL DRINKING; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARBAZOLES; ETHANOL; FATTY LIVER, ALCOHOLIC; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIVER; PROGNOSIS; PROPANOLAMINES; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910646076     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i40.14672     Document Type: Review

References (147)

1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1575-1586 [PMID: 23993280 DOI: 10.1016/S0140-6736(13)61611-6]
2. Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol 2013; 59: 160-168 [PMID: 23511777 DOI: 10.1016/j.jhep.2013.03.007]
3. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-1714 [PMID: 18471548 DOI: 10.1053/j.gastro.2008.02.069]
4. Seitz HK, Becker P. Alcohol metabolism and cancer risk. Alcohol Res Health 2007; 30: 38-41, 44-7 [PMID: 17718399]
5. Ong J, Younossi ZM. Non-alcoholic fatty liver disease after liver transplantation: a case of nurture and nature. Am J Gastroenterol 2010; 105: 621-623 [PMID: 20203643 DOI: 10.1038/ajg.2009.720]
6. Nelson S, Kolls JK. Alcohol, host defence and society. Nat Rev Immunol 2002; 2: 205-209 [PMID: 11913071]
7. Haber PS, Warner R, Seth D, Gorrell MD, McCaughan GW. Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol 2003; 18: 1332-1344 [PMID: 14675260]
8. Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 1991; 86: 210-216 [PMID: 1992635]
9. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004; 34: 9-19 [PMID: 15670660]
10. Hakucho A, Liu J, Liu X, Fujimiya T. Carvedilol improves ethanol-induced liver injury via modifying the interaction between oxidative stress and sympathetic hyperactivity in rats. Hepatol Res 2014; 44: 560-570 [PMID: 23607506 DOI: 10.1111/hepr.12143]
11. Tsujimoto I, Moriya K, Sakai K, Dickneite G, Sakai T. Critical role of factor XIII in the initial stages of carbon tetrachloride-induced adult liver remodeling. Am J Pathol 2011; 179: 3011-3019 [PMID: 22019897 DOI: 10.1016/j.ajpath.2011.08.037]
12. Liu J, Takase I, Hakucho A, Okamura N, Fujimiya T. Carvedilol attenuates the progression of alcohol fatty liver disease in rats. Alcohol Clin Exp Res 2012; 36: 1587-1599 [PMID: 22413959 DOI: 10.1111/j.1530-0277.2012.01773.x]
13. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152 [PMID: 15254578]
14. Otani K, Korenaga M, Beard MR, Li K, Qian T, Showalter LA, Singh AK, Wang T, Weinman SA. Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 2005; 128: 96-107 [PMID: 15633127]
15. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-1213 [PMID: 12395331]
16. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85: 498-502 [PMID: 10699921]
17. Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 2012; 61: 141-152 [PMID: 22372457 DOI: 10.1111/j.1365-2559.2011.04145.x]
18. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-678 [PMID: 12406438]
19. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850 [PMID: 9462221]
20. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250 [PMID: 10644669]
21. Seitz HK, Stickel F. Acetaldehyde as an underestimated risk factor for cancer development: role of genetics in ethanol metabolism. Genes Nutr 2010; 5: 121-128 [PMID: 19847467 DOI: 10.1007/s12263-009-0154-1]
22. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010; 51: 307-328 [PMID: 20034030 DOI: 10.1002/hep.23258]
23. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27: 44-54 [PMID: 17295176]
24. Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, Schaefer C, Lieber CS. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001; 25: 502-507 [PMID: 11329488]
25. Everitt H, Hu M, Ajmo JM, Rogers CQ, Liang X, Zhang R, Yin H, Choi A, Bennett ES, You M. Ethanol administration exacerbates the abnormalities in hepatic lipid oxidation in genetically obese mice. Am J Physiol Gastrointest Liver Physiol 2013; 304: G38-G47 [PMID: 23139221 DOI: 10.1152/ajpgi.00309.2012]
26. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35: 635-638 [PMID: 11870378]
27. Li TK. Quantifying the risk for alcohol-use and alcohol-attributable health disorders: present findings and future research needs. J Gastroenterol Hepatol 2008; 23 Suppl 1: S2-S8 [PMID: 18336658 DOI: 10.1111/j.1440-1746.2007.05298.x]
28. Jin M, Cai S, Guo J, Zhu Y, Li M, Yu Y, Zhang S, Chen K. Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol 2013; 24: 807-816 [PMID: 23104725 DOI: 10.1093/annonc/mds508]
29. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J Gastroenterol 2007; 13: 4699-4706 [PMID: 17729391]
30. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 2006; 290: G199-G203 [PMID: 16407589]
31. Reed T, Page WF, Viken RJ, Christian JC. Genetic predisposition to organ-specific endpoints of alcoholism. Alcohol Clin Exp Res 1996; 20: 1528-1533 [PMID: 8986199]
32. Fisher NC, Hanson J, Phillips A, Rao JN, Swarbrick ET. Mortality from liver disease in the West Midlands, 1993-2000: observational study. BMJ 2002; 325: 312-313 [PMID: 12169508]
33. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]
34. Trépo E, Gustot T, Degré D, Lemmers A, Verset L, Demetter P, Ouziel R, Quertinmont E, Vercruysse V, Amininejad L, Deltenre P, Le Moine O, Devière J, Franchimont D, Moreno C. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011; 55: 906-912 [PMID: 21334404 DOI: 10.1016/j.jhep.2011.01.028]
35. Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen H, Günther R, Arlt A, Seeger M, Müller S, Seitz HK, Soyka M, Lerch M, Lammert F, Sarrazin C, Kubitz R, Häussinger D, Hellerbrand C, Bröring D, Schreiber S, Kiefer F, Spanagel R, Mann K, Datz C, Krawczak M, Wodarz N, Völzke H, Hampe J. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011; 53: 86-95 [PMID: 21254164 DOI: 10.1002/hep.24017]
36. Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut 2012; 61: 150-159 [PMID: 22110053 DOI: 10.1136/gutjnl-2011-301239]
37. Schuckit MA. Alcohol and alcoholism. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of internal medicine. New York: McGraw-Hill Medical Publishing Division, 2005: 2562-2566
38. Mello T, Ceni E, Surrenti C, Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008; 29: 17-21 [PMID: 18164754 DOI: 10.1016/j.mam.2007.10.001]
39. Kane AB, Kumar V. Environmental and nutritional pathology. In: Cotran RS, Kumar V, Collins T, editors. Pathologic basis of disease. Philadephia: W.B. Saunders Company, 1999: 40-457
40. Israel Y, Kalant H, Khanna JM, Orrego H, Phillips MJ, Stewart DJ. Ethanol metabolism, oxygen availability and alcohol induced liver damage. Adv Exp Med Biol 1977; 85A: 343-358 [PMID: 920490]
41. Ugarte G, Iturriaga H, Pereda T. Possible relationship between the rate of ethanol metabolism and the severity of hepatic damage in chronic alcoholics. Am J Dig Dis 1977; 22: 406-410 [PMID: 857661]
42. Yamashita H, Kaneyuki T, Tagawa K. Production of acetate in the liver and its utilization in peripheral tissues. Biochim Biophys Acta 2001; 1532: 79-87 [PMID: 11420176]
43. Sakakibara I, Fujino T, Ishii M, Tanaka T, Shimosawa T, Miura S, Zhang W, Tokutake Y, Yamamoto J, Awano M, Iwasaki S, Motoike T, Okamura M, Inagaki T, Kita K, Ezaki O, Naito M, Kuwaki T, Chohnan S, Yamamoto TT, Hammer RE, Kodama T, Yanagisawa M, Sakai J. Fasting-induced hypothermia and reduced energy production in mice lacking acetyl-CoA synthetase 2. Cell Metab 2009; 9: 191-202 [PMID: 19187775 DOI: 10.1016/j.cmet.2008.12.008]
44. Watkins PA, Maiguel D, Jia Z, Pevsner J. Evidence for 26 distinct acyl-coenzyme A synthetase genes in the human genome. J Lipid Res 2007; 48: 2736-2750 [PMID: 17762044]
45. Moghe A, Joshi-Barve S, Ghare S, Gobejishvili L, Kirpich I, McClain CJ, Barve S. Histone modifications and alcohol-induced liver disease: are altered nutrients the missing link? World J Gastroenterol 2011; 17: 2465-2472 [PMID: 21633651 DOI: 10.3748/wjg.v17.i20.2465]
46. Kendrick SF, O'Boyle G, Mann J, Zeybel M, Palmer J, Jones DE, Day CP. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. Hepatology 2010; 51: 1988-1997 [PMID: 20232292 DOI: 10.1002/hep.23572]
47. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-544 [PMID: 9114822]
48. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306 [PMID: 11580156]
49. Seth D, Haber PS, Syn WK, Diehl AM, Day CP. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol 2011; 26: 1089-1105 [PMID: 21545524 DOI: 10.1111/j.1440-1746.2011.06756.x]
50. Soderberg BL, Salem RO, Best CA, Cluette-Brown JE, Laposata M. Fatty acid ethyl esters. Ethanol metabolites that reflect ethanol intake. Am J Clin Pathol 2003; 119 Suppl: S94-S99 [PMID: 12951847]
51. Kaphalia BS, Cai P, Khan MF, Okorodudu AO, Ansari GA. Fatty acid ethyl esters: markers of alcohol abuse and alcoholism. Alcohol 2004; 34: 151-158 [PMID: 15902908]
52. Nagy LE. Molecular aspects of alcohol metabolism: transcription factors involved in early ethanol-induced liver injury. Annu Rev Nutr 2004; 24: 55-78 [PMID: 15189113]
53. Salaspuro MP, Shaw S, Jayatilleke E, Ross WA, Lieber CS. Attenuation of the ethanol-induced hepatic redox change after chronic alcohol consumption in baboons: metabolic consequences in vivo and in vitro. Hepatology 1981; 1: 33-38 [PMID: 6793493]
54. Day CP. Treatment of alcoholic liver disease. Liver Transpl 2007; 13: S69-S75 [PMID: 17969070]
55. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-1476 [PMID: 11078773]
56. Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J Investig Med 1995; 43: 227-235 [PMID: 7614068]
57. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, Thurman RG. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999; 117: 942-952 [PMID: 10500078]
58. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287: G497-G502 [PMID: 15331349]
59. Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, Yamashina S, Schemmer P, Kitamura T, Oide H, Takei Y, Hirose M, Shimizu H, Miyazaki A, Brenner DA, Sato N, Thurman RG. Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J Gastroenterol Hepatol 2000; 15 Suppl: D20-D25 [PMID: 10759216]
60. McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993; 13: 170-182 [PMID: 8337603]
61. Parlesak A, Schäfer C, Schütz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000; 32: 742-747 [PMID: 10845660]
62. Choudhry MA, Fazal N, Goto M, Gamelli RL, Sayeed MM. Gut-associated lymphoid T cell suppression enhances bacterial translocation in alcohol and burn injury. Am J Physiol Gastrointest Liver Physiol 2002; 282: G937-G947 [PMID: 12016118]
63. Uesugi T, Froh M, Arteel GE, Bradford BU, Wheeler MD, Gäbele E, Isayama F, Thurman RG. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002; 168: 2963-2969 [PMID: 11884468]
64. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433 [PMID: 1698311]
65. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-1196 [PMID: 15102878]
66. Feingold KR, Hardardóttir I, Grunfeld C. Beneficial effects of cytokine induced hyperlipidemia. Z Ernahrungswiss 1998; 37 Suppl 1: 66-74 [PMID: 9558731]
67. Nachiappan V, Curtiss D, Corkey BE, Kilpatrick L. Cytokines inhibit fatty acid oxidation in isolated rat hepatocytes: synergy among TNF, IL-6, and IL-1. Shock 1994; 1: 123-129 [PMID: 7749930]
68. Stepniakowski KT, Sallee FR, Goodfriend TL, Zhang Z, Egan BM. Fatty acids enhance neurovascular reflex responses by effects on alpha 1-adrenoceptors. Am J Physiol 1996; 270: R1340-R1346 [PMID: 8764302]
69. Grekin RJ, Dumont CJ, Vollmer AP, Watts SW, Webb RC. Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion. Am J Physiol 1997; 273: R324-R330 [PMID: 9249567]
70. Liu J, Fujimiya T. Abrupt termination of an ethanol regimen provokes ventricular arrhythmia and enhances susceptibility to the arrhythmogenic effects of epinephrine in rats. Alcohol Clin Exp Res 2010; 34 Suppl 1: S45-S53 [PMID: 19094192 DOI: 10.1111/j.1530-0277.2008.00851.x]
71. Berg T, Walaas SI, Roberg BA˚, Huynh TT, Jensen J. Plasma Norepinephrine in Hypertensive Rats Reflects α(2)-Adrenoceptor Release Control Only When Re-Uptake is Inhibited. Front Neurol 2012; 3: 160 [PMID: 23162530 DOI: 10.3389/fneur.2012.00160]
72. Hamasaki K, Nakashima M, Naito S, Akiyama Y, Ohtsuru A, Hamanaka Y, Hsu CT, Ito M, Sekine I. The sympathetic nervous system promotes carbon tetrachloride-induced liver cirrhosis in rats by suppressing apoptosis and enhancing the growth kinetics of regenerating hepatocytes. J Gastroenterol 2001; 36: 111-120 [PMID: 11227667]
73. von Montfort C, Beier JI, Guo L, Kaiser JP, Arteel GE. Contribution of the sympathetic hormone epinephrine to the sensitizing effect of ethanol on LPS-induced liver damage in mice. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1227-G1234 [PMID: 18325983 DOI: 10.1152/ajpgi.00050.2008]
74. Ajakaiye MA, Jacob A, Wu R, Zhou M, Ji Y, Dong W, Wang Z, Qiang X, Chaung WW, Nicastro J, Coppa GF, Wang P. Upregulation of Kupffer cell α2A-Adrenoceptors and downregulation of MKP-1 mediate hepatic injury in chronic alcohol exposure. Biochem Biophys Res Commun 2011; 409: 406-411 [PMID: 21575605 DOI: 10.1016/j.bbrc.2011.05.007]
75. Higashiyama R, Inagaki Y, Hong YY, Kushida M, Nakao S, Niioka M, Watanabe T, Okano H, Matsuzaki Y, Shiota G, Okazaki I. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007; 45: 213-222 [PMID: 17187438]
76. Kallis YN, Alison MR, Forbes SJ. Bone marrow stem cells and liver disease. Gut 2007; 56: 716-724 [PMID: 17145739]
77. Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, Yarmush ML. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem Biophys Res Commun 2007; 363: 247-252 [PMID: 17869217]
78. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, Iredale JP, Forbes SJ. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006; 130: 1807-1821 [PMID: 16697743]
79. Fujimiya T, Liu J, Kojima H, Shirafuji S, Kimura H, Fujimiya M. Pathological roles of bone marrow-derived stellate cells in a mouse model of alcohol-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2009; 297: G451-G460 [PMID: 19608736 DOI: 10.1152/ajpgi.00055.2009]
80. Lawler JF, Yin M, Diehl AM, Roberts E, Chatterjee S. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem 1998; 273: 5053-5059 [PMID: 9478955]
81. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood) 2007; 232: 614-621 [PMID: 17463157]
82. Donohue TM. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007; 13: 4974-4978 [PMID: 17854140]
83. Tai ES, bin Ali A, Zhang Q, Loh LM, Tan CE, Retnam L, El Oakley RM, Lim SK. Hepatic expression of PPARalpha, a molecular target of fibrates, is regulated during inflammation in a gender-specific manner. FEBS Lett 2003; 546: 237-240 [PMID: 12832047]
84. Pritchard MT, Nagy LE. Ethanol-induced liver injury: potential roles for egr-1. Alcohol Clin Exp Res 2005; 29: 146S-150S [PMID: 16344600]
85. Thomes PG, Osna NA, Davis JS, Donohue TM. Cellular steatosis in ethanol oxidizing-HepG2 cells is partially controlled by the transcription factor, early growth response-1. Int J Biochem Cell Biol 2013; 45: 454-463 [PMID: 23103837 DOI: 10.1016/j.biocel.2012.10.002]
86. Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) 2012; 237: 1-9 [PMID: 22238286 DOI: 10.1258/ebm.2011.011255]
87. Fearns C, Loskutoff DJ. Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol 1997; 150: 579-590 [PMID: 9033272]
88. Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, Luyendyk JP, Roth RA, Arteel GE. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130: 2099-2112 [PMID: 16762632]
89. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99: 838-845 [PMID: 9062340]
90. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc Natl Acad Sci USA 1995; 92: 935-938 [PMID: 7862668]
91. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002; 277: 29342-29347 [PMID: 12036955]
92. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory elementbinding protein-2. J Clin Invest 1998; 101: 2331-2339 [PMID: 9616204]
93. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010; 16: 1321-1329 [PMID: 20238398 DOI: 10.3748/wjg.v16.i11.1321]
94. Lluis JM, Colell A, García-Ruiz C, Kaplowitz N, Ferńndez-Checa JC. Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress. Gastroenterology 2003; 124: 708-724 [PMID: 12612910]
95. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98: 1575-1584 [PMID: 8833906]
96. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 2002; 277: 19353-19357 [PMID: 11923308]
97. García-Villafranca J, Guillén A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie 2008; 90: 460-466 [PMID: 17997005]
98. You M, Crabb DW. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1-G6 [PMID: 15194557]
99. Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, Mounier R, Andreelli F, Foretz M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) 2009; 196: 81-98 [PMID: 19245656 DOI: 10.1111/j.1748-1716.2009.01970.x]
100. Ruderman NB, Park H, Kaushik VK, Dean D, Constant S, Prentki M, Saha AK. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003; 178: 435-442 [PMID: 12864749]
101. Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, Campbell-Thompson M, Crawford J, Shek EW, Scarpace PJ, Zolotukhin S. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA 2003; 100: 14217-14222 [PMID: 14617771]
102. Supakul R, Liangpunsakul S. Alcoholic-induced hepatic steatosis - role of ceramide and protein phosphatase 2A. Transl Res 2011; 158: 77-81 [PMID: 21757150 DOI: 10.1016/j.trsl.2011.03.005]
103. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100 [PMID: 12840063]
104. Yu S, Rao S, Reddy JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 2003; 3: 561-572 [PMID: 14527087]
105. Munday MR, Hemingway CJ. The regulation of acetyl-CoA carboxylase - a potential target for the action of hypolipidemic agents. Adv Enzyme Regul 1999; 39: 205-234 [PMID: 10470374]
106. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002; 277: 4098-4103 [PMID: 11734553]
107. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103: 1489-1498 [PMID: 10359558]
108. Wagner M, Zollner G, Trauner M. Nuclear receptors in liver disease. Hepatology 2011; 53: 1023-1034 [PMID: 21319202 DOI: 10.1002/hep.24148]
109. Galli A, Pinaire J, Fischer M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J Biol Chem 2001; 276: 68-75 [PMID: 11022051]
110. Lu Y, Zhuge J, Wang X, Bai J, Cederbaum AI. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology 2008; 47: 1483-1494 [PMID: 18393316 DOI: 10.1002/hep.22222]
111. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003; 278: 27997-28004 [PMID: 12791698]
112. Lebrun V, Molendi-Coste O, Lanthier N, Sempoux C, Cani PD, van Rooijen N, Stärkel P, Horsmans Y, Leclercq IA. Impact of PPAR-α induction on glucose homoeostasis in alcohol-fed mice. Clin Sci (Lond) 2013; 125: 501-511 [PMID: 23758436 DOI: 10.1042/CS20130064]
113. Breitkopf K, Nagy LE, Beier JI, Mueller S, Weng H, Dooley S. Current experimental perspectives on the clinical progression of alcoholic liver disease. Alcohol Clin Exp Res 2009; 33: 1647-1655 [PMID: 19645734 DOI: 10.1111/j.1530-0277.2009.01015.x]
114. Kruithof EK. Plasminogen activator inhibitors - a review. Enzyme 1988; 40: 113-121 [PMID: 3139400]
115. Dimmitt SB, Rakic V, Puddey IB, Baker R, Oostryck R, Adams MJ, Chesterman CN, Burke V, Beilin LJ. The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial. Blood Coagul Fibrinolysis 1998; 9: 39-45 [PMID: 9607117]
116. Tran-Thang C, Fasel-Felley J, Pralong G, Hofstetter JR, Bachmann F, Kruithof EK. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62: 651-653 [PMID: 2510345]
117. Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G, Van Marck E, Staels B, Michielsen P, Van Gaal L. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2014; 59: 121-129 [PMID: 24375485 DOI: 10.1002/hep.26510]
118. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008; 100: 992-1006 [PMID: 19132222]
119. Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-346 [PMID: 14747283]
120. Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010; 209: 585-591 [PMID: 19896127 DOI: 10.1016/j.atherosclerosis.2009.10.011]
121. Gashler A, Sukhatme VP. Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 1995; 50: 191-224 [PMID: 7754034]
122. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, Pinsky DJ, Stern DM. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000; 6: 1355-1361 [PMID: 11100120]
123. Kishore R, Hill JR, McMullen MR, Frenkel J, Nagy LE. ERK1/2 and Egr-1 contribute to increased TNF-alpha production in rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol 2002; 282: G6-15 [PMID: 11751152]
124. Shi L, Kishore R, McMullen MR, Nagy LE. Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages: contribution to enhanced tumor necrosis factor alpha production. J Biol Chem 2002; 277: 14777-14785 [PMID: 11856733]
125. Bertolani C, Marra F. Role of adipocytokines in hepatic fibrosis. Curr Pharm Des 2010; 16: 1929-1940 [PMID: 20370673]
126. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28 [PMID: 16406828]
127. Suh SK, Hood BL, Kim BJ, Conrads TP, Veenstra TD, Song BJ. Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics 2004; 4: 3401-3412 [PMID: 15449375]
128. Sid B, Verrax J, Calderon PB. Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. Biochem Pharmacol 2013; 86: 200-209 [PMID: 23688501 DOI: 10.1016/j.bcp.2013.05.007]
129. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-948 [PMID: 16612386]
130. Gao B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol 2012; 27 Suppl 2: 89-93 [PMID: 22320924 DOI: 10.1111/j.1440-1746.2011.07003.x]
131. El-Assal O, Hong F, Kim WH, Radaeva S, Gao B. IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004; 1: 205-211 [PMID: 16219169]
132. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004; 40: 933-941 [PMID: 15382116]
133. Miller AM, Wang H, Park O, Horiguchi N, Lafdil F, Mukhopadhyay P, Moh A, Fu XY, Kunos G, Pacher P, Gao B. Anti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injury. Alcohol Clin Exp Res 2010; 34: 719-725 [PMID: 20102572 DOI: 10.1111/j.1530-0277.2009.01141.x]
134. Sun Z, Klein AS, Radaeva S, Hong F, El-Assal O, Pan HN, Jaruga B, Batkai S, Hoshino S, Tian Z, Kunos G, Diehl AM, Gao B. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003; 125: 202-215 [PMID: 12851884]
135. Horiguchi N, Wang L, Mukhopadhyay P, Park O, Jeong WI, Lafdil F, Osei-Hyiaman D, Moh A, Fu XY, Pacher P, Kunos G, Gao B. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008; 134: 1148-1158 [PMID: 18395093 DOI: 10.1053/j.gastro.2008.01.016]
136. Mandal P, Park PH, McMullen MR, Pratt BT, Nagy LE. The anti-inflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010; 51: 1420-1429 [PMID: 20052772 DOI: 10.1002/hep.23427]
137. Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, Yin S, Lafdil F, Gao B. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin-10-deficient mice. Hepatology 2011; 54: 846-856 [PMID: 21725996 DOI: 10.1002/hep.24517]
138. An L, Wang X, Cederbaum AI. Cytokines in alcoholic liver disease. Arch Toxicol 2012; 86: 1337-1348 [PMID: 22367091 DOI: 10.1007/s00204-012-0814-6]
139. Kang L, Chen X, Sebastian BM, Pratt BT, Bederman IR, Alexander JC, Previs SF, Nagy LE. Chronic ethanol and triglyceride turnover in white adipose tissue in rats: inhibition of the anti-lipolytic action of insulin after chronic ethanol contributes to increased triglyceride degradation. J Biol Chem 2007; 282: 28465-28473 [PMID: 17686776]
140. Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol 2013; 28 Suppl 1: 77-84 [PMID: 23855300 DOI: 10.1111/jgh.12030]
141. Dhanda AD, Lee RW, Collins PL, McCune CA. Molecular targets in the treatment of alcoholic hepatitis. World J Gastroenterol 2012; 18: 5504-5513 [PMID: 23112542 DOI: 10.3748/wjg.v18.i39.5504]
142. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-1762 [PMID: 20102716 DOI: 10.1053/j.gastro.2010.01.040]
143. Hellerbrand C. Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis. Dig Dis 2010; 28: 783-791 [PMID: 21525763 DOI: 10.1159/000324286]
144. Miyake T, Kumagi T, Furukawa S, Tokumoto Y, Hirooka M, Abe M, Hiasa Y, Matsuura B, Onji M. Non-alcoholic fatty liver disease: factors associated with its presence and onset. J Gastroenterol Hepatol 2013; 28 Suppl 4: 71-78 [PMID: 24251708 DOI: 10.1111/jgh.12251]
145. Cassano N, Vestita M, Apruzzi D, Vena GA. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. Int J Dermatol 2011; 50: 1323-1331 [PMID: 22004481 DOI: 10.1111/j.1365-4632.2011.05100]
146. Iglesias E, Torrente-Segarra V, Bou R, Ricart S, González MI, Sánchez J, Calzada J, Antón J. Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment. Rheumatol Int 2014; 34: 1053-1057 [PMID: 24162563 DOI: 10.1007/s00296-013-2884-z]
147. Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther 2013; 3: 1-14 [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1]